Search - tctmd.com

Displaying 41 - 60 of 265

Sort: Relevancy | Date

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

February 15, 2024

Radial Access for Acute Stroke Interventions Takes Longer, No Safety Gains

News Conference News ISC 2024

Radial Access for Acute Stroke Interventions Takes Longer, No Safety Gains

February 12, 2024

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

August 30, 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

News Conference News ESC 2023

FRAIL-AF: Warfarin Beats NOACs in Frail Elderly With AF

August 28, 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

News Conference News ESC 2023

NOAH-AFNET 6: Edoxaban for Atrial High-Rate Episodes: No Help, Some Harm

August 25, 2023

ECST-2: No Benefit of Carotid Revascularization on Top of Best Medical Therapy

News Conference News ESOC 2023

ECST-2: No Benefit of Carotid Revascularization on Top of Best Medical Therapy

May 26, 2023

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

News Conference News ESOC 2023

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

May 25, 2023

ELAN: Early DOACs Safe, May Help After Ischemic Stroke in AF Patients

News Conference News ESOC 2023

ELAN: Early DOACs Safe, May Help After Ischemic Stroke in AF Patients

May 24, 2023

AnchorMan LAAO Device Matches Up Well With the Watchman

News Conference News EuroPCR 2023

AnchorMan LAAO Device Matches Up Well With the Watchman

May 19, 2023

ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure

News Conference News EuroPCR 2023

ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure

May 18, 2023

Does All AF After Stroke Warrant Anticoagulation? Experts Debate

News Conference News ISC 2023

Does All AF After Stroke Warrant Anticoagulation? Experts Debate

February 17, 2023

BEST-CLI: Experts at ISET Look to Bridge Research Results and Practice

News Conference News ISET 2023

BEST-CLI: Experts at ISET Look to Bridge Research Results and Practice

January 25, 2023

The PE Pipeline: Evidence Trickles in for Catheter-Based Therapies

News Conference News ISET 2023

The PE Pipeline: Evidence Trickles in for Catheter-Based Therapies

January 23, 2023

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

November 11, 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

November 06, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.